Abhishek Santosh Gosavi

Mr. Abhishek Santosh Gosavi

Aten porus life sciences pvt ltd, Bengaluru, India
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Oral Oncology
Verified
Journal Article
Closed access
ACAmbika Chamoli
Ambika Chamoli
AGAbhishek Santosh Gosavi
Abhishek Santosh Gosavi
USUrjita P. Shirwadkar
Urjita P. Shirwadkar
KWKhushal V. Wangdale
Khushal V. Wangdale
SBSantosh Kumar Behera
Santosh Kumar Behera
AMAmit Mandoli
Amit Mandoli

9 October 2022 in Molecules
Verified
Journal Article
Open access
PDF file
AGAVIJIT GOSWAMI
AVIJIT GOSWAMI
BDBarnali Deb
Barnali Deb
SGSandeep Goyal
Sandeep Goyal
AGAbhishek Santosh Gosavi
Abhishek Santosh Gosavi
MMMukund Mali
Mukund Mali
AKAditya Kulkarni
Aditya Kulkarni
Cyclic GMP-AMP synthase (cGAS) is an endogenous DNA sensor that synthesizes cyclic guanosine monophosphate–adenosine monophosphate (2′3′-cGAMP) from ATP and GTP. 2′3′-cGAMP activates the stimulator of interferon genes (STING) pathway, resulting in the production of interferons and pro-inflammatory cytokines. Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) is the phosphodiesterase that negatively regulates the STING pathway by hydrolyzing 2′3′-cGAMP. It has been established that the cGAS–STING pathway plays a major role in inhibiting tumor growth by upregulating T cell response. Herein, we demonstrate that AVA-NP-695, a selective and highly potent ENPP1 inhibitor, apart from the immunomodulatory effect also modulates cancer metastasis by negatively regulating epithelial–mesenchymal transition (EMT). We established that the combined addition of 2′3′-cGAMP and AVA-NP-695 significantly abrogated the transforming growth factor beta (TGF-ꞵ)-induced EMT in MDA-MB-231 cells. Finally, results from the in vivo study showed superior tumor growth inhibition and impact on tumor metastasis of AVA-NP-695 compared to Olaparib and PD-1 in a syngeneic 4T1 breast cancer mouse model. The translation of efficacy from in vitro to in vivo 4T1 tumor model provides a strong rationale for the therapeutic potential of AVA-NP-695 against triple-negative breast cancer (TNBC) as an immunomodulatory and anti-metastatic agent.